Perlmutter and Greig proposed for Ablynx board
This article was originally published in Scrip
Executive Summary
Ablynx has put forward Drs Roger Perlmutter and Russell Greig as candidates to be appointed independent non-executive directors. The company will vote at the extraordinary general meeting of its shareholders at the beginning of November. Dr Perlmutter, currently a director of StemCells Inc and Immune Design Corporation, was previously executive vice-president of research and development at Amgen. Dr Greig spent the majority of his career at GlaxoSmithKline where he most recently served as president of pharmaceuticals international from 2003-2008.